AdhereRx to Open New High-Tech Pharmacy in Phoenix, Arizona

NASHVILLE, Tenn., March 18, 2020 /PRNewswire/ — AdhereRx, a subsidiary of AdhereHealth, announced plans to open a new high-tech pharmacy in Phoenix, Arizona. The new 18,000-square-foot facility will enable AdhereRx to better support managed care organizations and providers serving patients with chronic conditions.

“This new facility comes at a crucial time. We were already experiencing a spike in demand for our unique AdhereRx pharmacy, which has now been magnified by the recent spread of COVID-19 and guidance for social distancing – especially for the elderly and high-risk patients,” said Jason Z. Rose, CEO at AdhereHealth. “The need to expand our pharmacy operations is greater than ever. We hope to ease the concerns of patients by ensuring continued access to medications, which in turn will prevent additional strains on our healthcare system.”

AdhereRx is a high-touch pharmacy for medically complex patients with challenging social determinants of health who benefit from private courier delivery. The team of licensed pharmacists and pharmacy technicians work seamlessly with managed care organizations and their providers to support patient care with services such as:

  • Ongoing predictive analytics to identify high-risk patients and drug therapy problems
  • Personalized medication regimens with monthly synchronization to help remove adherence barriers
  • Private HIPAA-certified couriers to deliver medications, including Schedule III-V controlled substances
  • Financial assistance and cash on delivery options

AdhereRx has been in business for more than 15 years and already operates a high-volume pharmacy in Cary, North Carolina. The new facility in Phoenix will be equipped with state-of-the-art technology, including specialized cameras and robotic systems to automatically and remotely package prescriptions. The grand opening is scheduled for spring 2020.

To learn more about AdhereRx courier pharmacy service, please visit the AdhereRx website.

About AdhereHealth™
AdhereHealth is a healthcare technology solutions leader supporting health plans, self-insured employers, and other risk-bearing entities for medication adherence insights and improved healthcare outcomes. The company’s Adhere™ platform touches nearly 30 million consumers through advanced technologies and at-risk engagement services. AdhereHealth’s subsidiary company, AdhereRx, is a free concierge pharmacy for consumers with high-risk chronic conditions and social determinants of health issues. AdhereRx coordinates complex medication regimens, performs monthly comprehensive medication reviews (CMR) and drug utilization reviews (DUR), has 24/7 access to pharmacy clinicians, delivers prescriptions via a private courier service, supports those in need of financial assistance, and can take cash on delivery at the consumer’s home. This integrated set of solutions addresses an estimated half a trillion dollars of unnecessary annual medical costs attributed to medication adherence issues. The company is headquartered in the Nashville suburb of Franklin, Tennessee. For more information, please visit www.adherehealth.com.

Media Contact:

Andrea LePain
eMedia Junction
andrea@emediajunction.com 
617-275-8112

View original content to download multimedia:http://www.prnewswire.com/news-releases/adhererx-to-open-new-high-tech-pharmacy-in-phoenix-arizona-301026190.html

SOURCE AdhereHealth

Staff

Recent Posts

RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION

SINGAPORE, Dec. 7, 2025 /PRNewswire/ -- AI/ML health-tech startup Respiree has received approval from the Health…

31 minutes ago

AI-for-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab for Drug Discovery in Singapore

SINGAPORE, Dec. 7, 2025 /PRNewswire/ -- ChemLex, a next-generation AI-for-science company, today announced the establishment…

31 minutes ago

Is The DEA in Systemic Collapse: Corruption, Constitutional Violations, and a Seven-Year War Against Marijuana Medical Science

The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…

15 hours ago

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…

15 hours ago

Secura Bio Presents Extended Follow Up Analyses from Phase 2 PRIMO Trial in Patients with Relapsed/Refractory peripheral T-cell lymphoma at the 2025 American Society of Hematology Meeting

Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…

15 hours ago